Pharmascience Implements OpenText Document Management
OpenText, a global market information management solutions company, announced that Pharmascience, a Canadian manufacturer of branded and generic pharma drugs, has deployed OpenText Content Suite to manage its documents.
Pharmascience produces over 2,000 products with sales in over 60 countries worldwide. In Canada alone, more than 45 million prescriptions a year are filled with Pharmascience products. The company needed an Enterprise Content Management (ECM) solution to manage and secure its document lifecycle and help respond to increasing regulatory demands. It needed document governance tools, including workflow management, version control, and audit trails.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
